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AbstrACt
Objectives Although tobacco is the leading preventable 
cause of death in the USA, it is routinely sold in 
pharmacies. In 2008, San Francisco became the first city 
in the USA to pass a tobacco-free pharmacy ordinance. 
Over the next decade, 171 municipalities enacted similar 
policies, and in 2018, Massachusetts banned tobacco 
sales in pharmacies. Our objective was to assess the 
perceived effects of tobacco-free pharmacy policies on 
displays, sales, customer visits and counselling.
Design Observational study and survey.
setting In 2017, we visited Walgreens and CVS stores in 
San Francisco and nearby San Jose, which allows tobacco 
sales, to assess placement of tobacco and over-the-
counter tobacco cessation products (nicotine replacement 
therapy or NRT). We surveyed an employee at each site 
regarding the impact that tobacco-free pharmacy policies 
had had on customer traffic and sales of NRT.
Participants We obtained display data from 72 
pharmacies and collected surveys from 55 employees 
(76% response rate).
results A majority of respondents at tobacco-free 
pharmacies (55%) reported that the policy had not affected 
customer visits. In comparison, 70% of respondents at 
tobacco-selling pharmacies believed that eliminating 
tobacco sales would reduce the number of customers 
visiting their stores. Pharmacies that were tobacco free 
and those that sold tobacco reported comparable displays, 
sales and counselling for NRT.
Conclusions Pharmacies operating under tobacco-free 
policies did not report reduced customer visits. Greater 
awareness of this outcome could help pharmacies 
implement public health recommendations to eliminate 
tobacco sales.
IntrODuCtIOn
Tobacco is the leading preventable cause 
of death in the USA, causing over 480 000 
deaths per year.1 In most high-income coun-
tries pharmacies do not sell tobacco,2 but in 
the USA this is common; an estimated 80% 
of prescriptions in 2014 were filled at phar-
macies that sell tobacco.3–5 Pharmacies that 
sell tobacco are also more likely to encourage 
its use; tobacco prices are lower in pharma-
cies relative to other stores,6 and chain phar-
macies are more likely than independents 
to stock tobacco products and sell them to 
minors.7–11 Pharmacies also sell tobacco prod-
ucts and promote smoking in low-income and 
middle-income countries (LMICs).12 13 
Tobacco sales in US pharmacies persist 
despite calls to ban the practice by multiple 
health organisations,3 the finding that only 
2% of pharmacists favour it2 and widespread 
public support for tobacco-free pharma-
cies.14–16 In LMICs, these sales persist even 
in countries that are part of the Framework 
Convention on Tobacco Control.13 US chain 
pharmacies are more likely to sell tobacco 
than independents4 and have expressed fears 
that they will lose sales as justification for the 
practice.17 18 This decision to sell tobacco has 
raised increasing questions as chain phar-
macies develop new ‘wellness store’ formats 
strengths and limitations of this study
 ► This paper provides new evidence about tobac-
co-free pharmacy policies at the community phar-
macy level. Other recent studies have focused on 
how these policies affect retailer density and smok-
ing prevalence.
 ► Our local study of cities with and without tobac-
co-free pharmacy policies updates older research 
on community pharmacies.
 ► Findings may be relevant to low-income and mid-
dle-income countries where pharmacies continue to 
sell tobacco.
 ► The study is limited by its focus on two municipal-
ities—San Francisco has a long-standing tobac-
co-free pharmacy ordinance and may differ from 
localities that have recently passed similar ordi-
nances—and its use of observational data.
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to expand access to primary care,2 given that providing 
healthcare (including smoking cessation) is inconsistent 
with selling tobacco, a deadly product.19–22
In 2008, San Francisco became the first city in the USA 
to establish standalone tobacco-free pharmacies; the 
ordinance was expanded in 2010.20 21 The CVS corpo-
ration discontinued sales of tobacco at all US locations 
in September 2014.23 By March 2018, 171 cities (the 
majority located in Massachusetts) had enacted tobac-
co-free pharmacy ordinances, less than 1% of US munic-
ipalities,24 25 and in July 2018, Massachusetts prohibited 
tobacco sales in pharmacies statewide.26 Studies suggest 
that tobacco-free pharmacies reduce retailer density,27–29 
and this reduced density leads to lower smoking initia-
tion and prevalence.30–38 Survey research has shown that 
both pharmacists and the general community support 
tobacco-free pharmacies after implementation,2 16 and 
media coverage has been favourable.39 Reports on sales 
and profitability after the CVS chain became tobacco free 
suggest that initial financial losses from eliminating 
tobacco sales in the first year22 30 40 were made up after 
the first year with increased sales of other products,41–43 
in particular, with increased sales of nicotine replacement 
therapy (NRT).44
Despite this work, there has been limited study on the 
perceived effects of tobacco-free pharmacy policies on 
pharmacies themselves. Although ownership of chain 
pharmacies is centralised, local policies may determine 
whether and how they sell tobacco.45 Salient questions 
include whether fears of reduced customer visits are 
valid, whether tobacco-selling pharmacies near tobac-
co-free localities change their displays to attract these 
potential lost customers, whether store layouts change 
after the elimination of tobacco ‘power walls’ behind 
cash registers46 and whether eliminating tobacco sales 
encourages customers to seek pharmacist assistance with 
smoking cessation. Existing studies of tobacco and NRT 
accessibility have assessed product availability by neigh-
bourhood within cities; however, these studies did not 
compare tobacco-selling and tobacco-free pharmacies or 
survey employees to identify reasons that products were 
or were not stocked.47 48
The goal of this study was to assess the perceived effects 
of tobacco-free pharmacy policies on chain pharmacies. 
We focused on three outcomes: (1) the display of tobacco 
products and over-the-counter nicotine NRT, (2) the 
perceived impact of a tobacco-free policy on customer 
visits and (3) whether stores reported that customers 
purchasing NRT received counselling from pharmacists.
MethODs
We conducted a cross-sectional study in chain pharma-
cies consisting of: (A) direct observation of product 
placements and (B) a survey of employees. This two-part 
study design made it possible to validate self-reports 
using observational data and identify justifications for 
different store display choices. The study included 
chain pharmacies in two localities: San Francisco, which 
passed a tobacco-free pharmacy law in 2008, and a 
nearby city, San Jose, which contained a roughly equiv-
alent number of stores. The primary chains operating 
in both cities were Walgreens and CVS; at the time of 
data collection, all Walgreens stores in San Jose were 
able to sell tobacco products (another major US phar-
macy chain, Rite Aid, had locations in San Jose but not 
in San Francisco and was excluded due to the absence 
of comparison cases). CVS stores had been tobacco-free 
throughout the USA since 2014 and served as a control 
case for both cities. We identified all pharmacies in each 
city by visiting each company’s website and searching 
by city name. After consulting with a regional manager 
for one chain, we explicitly excluded stores located in 
tourist areas (eg, Fisherman’s Wharf in San Francisco) 
because their business did not involve repeat customers, 
and their layouts and product lines (eg, souvenirs) 
were substantially different from those of other stores. 
We also excluded CVS branches located inside Target 
stores, because their store layouts were not controlled by 
CVS and their customer traffic included secondary visits 
made by Target shoppers.
We followed existing protocols for conducting observa-
tions of stores that sell tobacco, based on prior research, 
modified to reflect a study design containing only phar-
macies by removing assessments of measures such as store 
type.49 50 After completing online research training in 
collection of observational data and survey research, one 
study author (LP) visited all Walgreens and CVS phar-
macies that met the study inclusion criteria in April 2017 
during normal business hours (ranging between 08:00 
and 10:00). Data collected at each location included: (A) 
photographs of tobacco products and/or tobacco cessa-
tion products (NRT) on display; (B) measurements of the 
distance from the store entrance to each display; (C) a 
10-question survey completed by the store manager, assis-
tant manager or shift lead via the Qualtrics iPad appli-
cation; and (D) any additional information volunteered 
by survey respondents. Stores were revisited up to two 
times if no one was available to complete the survey on 
the initial visit.
The survey relied on a validated instrument created 
as part of a peer reviewed study of NRT sales in commu-
nity pharmacies in northern California.51 It was revised 
to include tobacco products based on input from a 
Walgreens store manager and UCSF tobacco control 
researchers. There were two versions of the survey instru-
ment: one for tobacco-free pharmacies and one for 
tobacco-selling pharmacies (see online supplementary 
appendix for survey instruments). The surveys requested 
verbal consent from participants followed by requests for 
information on locations of NRT and/or tobacco prod-
ucts to validate observational data, sales data, frequency 
of pharmacist smoking cessation counselling prior to 
consumer NRT purchase, factors that could impact 
product placement such as perceived theft risk and the 
perceived impact of tobacco-free pharmacy policies on 
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customer visits. Stata V.13 was used to conduct Fisher’s 
exact and Pearson’s χ2 tests of statistical significance.
Patient and public involvement: The study did not 
involve patients. Participants were not involved in plan-
ning the design, recruitment or conduct of the study 
and did not advise on the interpretation of the results 
or preparation of the manuscript. There are no plans to 
disseminate the study results to participants.
results
study characteristics
The corporate websites for Walgreens and CVS pharma-
cies identified 119 stores in San Francisco and San Jose. We 
excluded 47 of these stores on the grounds based on our 
exclusion criteria (located inside Target stores, in tourist 
areas or closed at the time of data collection), resulting in 
a total 72 stores in our sample. After visiting and surveying 
the stores in the sample, we obtained complete data on 
product placement for all stores (n=72); the response rate 
for the survey was 76% (n=55). The majority of surveys 
(n=35, 64%) were completed by store managers; in stores 
where the manager was not on site at the time of visit, 
the survey was completed by the assistant manager (n=18, 
33%) or the shift lead (n=2, 4%). Most of the pharmacies 
in our sample were operated by Walgreens (n=48, 67%). 
Overall, more stores were located in San Francisco (n=39, 
54%) than San Jose. Most stores in the sample (n=56, 
78%) did not sell tobacco. Characteristics of the sample 
and the survey respondents are provided in table 1.
Displays of tobacco products and nrt were similar within 
store type
Pharmacy product displays seek to both market through 
exposure by showing customers potential purchases and 
to limit access to products in order to prevent theft. The 
pharmacies in our sample placed NRT and (if relevant) 
tobacco products in similar locations.
Tobacco-selling pharmacies (Walgreens locations in 
San Jose only) placed tobacco products behind the cash 
registers, in the traditional ‘power wall’ position favoured 
by tobacco companies to drive tobacco product sales. 
These stores placed NRT directly adjacent to the tobacco 
products, as shown in figure 1. Survey reports were consis-
tent with these findings; respondents from tobacco-selling 
pharmacies reported that both tobacco and NRT prod-
ucts were stored behind the cash register (100%, n=10) 
and next to the entrance of the store (60%, n=6). Less 
than half of these respondents reported that NRT was at 
high risk of theft (n=3, 30%) or that the location of NRT 
products was influenced by the risk of theft. Results are 
shown in table 2.
Tobacco-free pharmacies (CVS stores in both cities 
and Walgreens stores in San Francisco) placed NRT 
in different locations depending on ownership. All 
Walgreens stores located NRT directly behind the cash 
registers, on the power wall. CVS stores placed NRT 
behind the cash registers on the power wall, as well as on 
aisle caps (see figure 1). Consistent with this evidence, 
NRT was located behind the cash registers (89% of sites) 
and at the front door entrance (38% of sites). Respon-
dents at tobacco-free pharmacies reported NRT was 
at high risk of theft (51%, n=23). Nearly half of these 
respondents (49%, n=22) stated that NRT product loca-
tion is impacted by theft; however, placing NRT behind 
a counter appeared to resolve the risk, given that few 
respondents reported that NRT was stored in locked bins 
(4%, n=2). Another 42% (n=19) of respondents reported 
that NRT placement was affected by other reasons such as 
store plan protocols (13%, n=6). Tobacco products and 
NRT were stored in comparable locations at all tobac-
co-selling pharmacies, and NRT was stored in the same 
locations in all tobacco-free pharmacies.
experience and expectations about customer visits in 
tobacco-free pharmacies differed by store type
We found significant differences in the perceived effects 
of tobacco-free policies on customer visits, which reflected 
whether the stores had actually implemented these poli-
cies. An overwhelming majority of respondents at tobac-
co-selling pharmacies believed that eliminating tobacco 
sales would result in fewer customers visiting the store. In 
contrast, most tobacco-free pharmacies, whether in San 
Francisco or operated by CVS, reported that eliminating 
tobacco sales had not resulted in reduced customer visits.
There were significant differences in expectations 
about customer traffic for tobacco-free pharmacies. 
Respondents from tobacco-selling pharmacies, 70% 
(n=7) reported that they believed fewer customers would 
visit their stores if tobacco product sales were eliminated. 
Despite this expectation, which implied that tobacco-pur-
chasing customers would change their shopping habits, 
90% of respondents (n=9) reported that they had not 
changed their tobacco product displays after competing 
Table 1 Sample characteristics
N Per cent
Pharmacies 72 100
  Company
   CVS 24 33
   Walgreens 48 67
  Location
   San Francisco 39 54
   San Jose 33 46
  Store type
   Tobacco free 56 78
   Tobacco selling 16 22
Survey respondents 55 100
  Position
   Store manager 35 64
   Assistant manager 18 33
   Shift lead 2 4
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stores stopped selling tobacco products. In contrast, a 
majority of tobacco-free pharmacy respondents reported 
that eliminating their tobacco product sales did not influ-
ence customer traffic (56%, n=25), where they placed 
NRT in the stores (78%, n=35) or NRT sales (60%, n=27). 
Results are shown in table 3.
We found no significant differences in reported NRT 
sales and reported tobacco product displays by store type 
Figure 1 Tobacco and NRT placements differ by pharmacy store type and owner: Walgreens behind cash registers; 
CVS behind cash registers and on end caps (San Francisco (SF) and San Jose (SJ)). (top left) NRT behind cash registers 
(Walgreens, SF); (top right) tobacco products behind cash registers (Walgreens, SJ); (middle left) NRT near pharmacy (CVS, SF); 
(middle right) NRT near pharmacy (CVS, J); (bottom left) NRT on cash register shelves (CVS, SF); and (bottom right) NRT on an 
aisle end (CVS, SJ). NRT, nicotine replacement therapy.
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(p=0.079). In contrast, the expectations of tobacco-selling 
pharmacy respondents were significantly different from 
the outcomes reported by tobacco-free pharmacy respon-
dents with respect to customer traffic (p=0.047).
Most customers purchased nrt without a pharmacist 
consultation
Most respondents from tobacco-selling pharmacies (70%, 
n=7) reported that customers rarely purchased NRT, that 
the overwhelming majority purchased NRT without a 
pharmacist consultation (80%, n=8) and that employees 
did not ask customers if they would like a pharmacist 
consultation prior to purchasing NRT. Similarly, most 
respondents from tobacco-free pharmacies (76%, n=34) 
reported that customers rarely purchased NRT, that an 
overwhelming majority purchased NRT without a phar-
macist consultation (73%, n=33) and that employees did 
not ask customers if they would like a pharmacist consul-
tation prior to purchasing NRT (89%, n=40). The differ-
ences between store types were not statistically significant.
DIsCussIOn
This study sought to expand on existing research reviewing 
tobacco-free policies by evaluating specific outcomes rele-
vant to pharmacies including reported customer visits to 
stores, reported NRT sales and observed NRT displays 
at pharmacies. Our findings suggest that tobacco-free 
pharmacies were not significantly different from tobac-
co-selling pharmacies with respect to any of these three 
outcomes. Chain pharmacies have expressed a belief that 
selling tobacco products attracts customers; however, our 
respondents reported that customer visits did not change 
when pharmacies stopped selling tobacco. Reported NRT 
sales were also comparable across store types. Our obser-
vational data found that stores had similar displays across 
the entire sample. Survey data revealed that displays often 
reflected store plan protocols created at the corporate 
level for all sites in a region, which is likely to have been 
responsible for the limited variation we observed.
We also considered potential differences in counsel-
ling requests for NRT. CVS as a corporation has reported 
overall increased NRT sales after implementing its tobac-
co-free policy,44 suggesting that sales of NRT, as well as 
customer expectations about the role of pharmacists 
in smoking cessation, could change after eliminating 
tobacco sales. The appropriate use of tobacco cessation 
aids is not always intuitive to new users; for example, 
nicotine gum should not be chewed repeatedly, and it 
can be combined with patches to reduce cravings.52 To 
assess whether customers were more likely to seek help 
Table 2 Survey responses addressing product placement
NRT Tobacco products
Placement behind cash register
Tobacco-free pharmacies 40 (89%) 0 (0%)
Tobacco-selling pharmacies 6 (60%) 10 (100%)
Fisher’s exact (p) 0.001
Placement by store entrance
Tobacco-free pharmacies 17 (38%) 0 (0%)
Tobacco-selling pharmacies 7 (70%) 6 (60%)
Fisher’s exact (p) 0.003
NRT, nicotine replacement therapy.
Table 3 Perceived effects of tobacco-free pharmacy policies
Increased Decreased No change
NRT sales, n (%)
Tobacco-free pharmacies* 13 (29) 2 (4) 27 (60)
Tobacco-selling pharmacies 0 (0) 1 (10) 9 (90)
Fisher’s exact (p) 0.079
Percent of customers who visit, n (%)
Tobacco-free pharmacies* 4 (9) 10 (22) 25 (55)
Tobacco-selling pharmacies 0 (0) 7 (70) 3 (30)
Fisher’s exact (p) 0.047
*Note: three respondents reported not knowing the NRT sales changes, and six respondents reported not knowing the impact on customers 
the law has had.
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in tobacco-free pharmacies, we asked respondents in 
tobacco-selling and tobacco-free pharmacies to indicate 
the likelihood of NRT purchasers seeking assistance from 
pharmacists. We found no differences between store 
types.
Previous research on tobacco sales in pharmacies has 
noted that selling tobacco conflicts with the self-iden-
tified mission of pharmacies, which is to promote the 
well-being of their customers.2 Before the passage of 
San Francisco’s tobacco-free pharmacy ordinance, the 
majority of the city’s pharmacies placed NRT products 
next to cigarettes.53 We found that tobacco-selling phar-
macies continued this product placement; like San Fran-
cisco pharmacies 15 years earlier, San Jose Walgreens 
stores placed NRT next to tobacco products. Combining 
these product displays is problematic, because it under-
cuts the purpose of smoking cessation aids by promoting 
tobacco. In addition, tobacco-selling pharmacies 
placed tobacco products by the entrance, a pivotal loca-
tion because it increases the convenience of tobacco 
purchases as well as advertising their use to everyone 
entering the store.46 The creation of the ‘power wall’ was 
based on tobacco industry research showing that placing 
cigarettes directly behind cash registers would repeatedly 
expose consumers to tobacco products and to positive 
messages about tobacco, increasing tobacco sales and 
use.46 Tobacco-free pharmacies, in contrast, typically 
replaced the tobacco products formerly sold in this loca-
tion with NRT, promoting tobacco cessation instead of 
tobacco use.
The employees we surveyed reported that over-the-
counter NRT was typically purchased without a pharmacist 
consultation and that employees (whether they them-
selves were pharmacists) did not suggest that purchasers 
consult a pharmacist. The purpose of NRT is to aid in 
smoking cessation by replacing the use of tobacco prod-
ucts, and with proper use and a tapering regimen, can help 
eliminate the addiction to nicotine.52 Information about 
how to use and taper NRT is one of counselling points 
that pharmacists can provide to people who are making 
a quit attempt. NRT is most effective when combined 
with counselling that helps identify and resolve smoking 
triggers; and patients who do not receive simultaneous 
counselling are likely to find NRT ineffective.54 55 Patients 
who do not receive counselling also have a greater risk 
of becoming addicted to NRT given that they may not be 
aware of when and how to properly taper down the nico-
tine content.52 Our research suggests that all pharmacies 
could be more assertive in encouraging NRT purchasers 
to consult with pharmacists at the time of sale.
Although we did not ask directly about perceptions on 
tobacco-free pharmacy policies, two survey respondents 
volunteered that they were preferred working at a tobac-
co-free pharmacy and that this change created a healthier 
environment for their community by removing tobacco 
advertising in the form of visible product placement. This 
stated preference for working in a tobacco-free pharmacy 
is consistent with previous research.56 Future studies could 
expand on these surveys by including the perceptions of 
other pharmacy employees, including management.
Our research has limitations. We focused on only two 
municipalities; because we chose to study San Francisco 
due to its long-standing tobacco-free pharmacy ordi-
nance, it is possible that our findings may not reflect the 
experience of localities that have recently passed similar 
ordinances. These two localities are primarily served by 
two chains, Walgreens and CVS; because CVS is now a 
tobacco-free pharmacy, our sample included only 16 
tobacco-selling pharmacies. Given recent efforts by the 
US Food and Drug Administration to curtail tobacco sales 
at Walgreens,8 a small share of tobacco-selling pharmacies 
may be increasingly representative of other localities. We 
could not survey pharmacies that had closed between the 
implementation of the San Francisco ordinance (or after 
CVS changed its policy in 2014) and our 2017 survey. 
Similarly, our research specifically excluded pharmacies 
in tourist areas and CVS locations within Target stores; 
these locations may have different displays and different 
customer interactions. Only one observer visited and 
photographed the study sites, potentially biasing findings 
and making it impossible to calculate inter-rater reliability. 
The research was cross-sectional in nature, which did not 
allow us to validate the perceived effects of tobacco-free 
pharmacy policies. The study did not explicitly address 
the availability of alternative tobacco products including 
e-cigarettes, little cigars and cigarillos, and smokeless 
tobacco, did not consider medications for cessation like 
varenicline and bupropion, which are not available over 
the counter in the USA, did not collect price data and 
did not validate respondent reports of sales with financial 
data because these data are proprietary.
Overall, our findings suggest that the concerns expressed 
by chain pharmacies that eliminating tobacco sales will 
reduce their customer traffic have not been borne out. 
In addition, the modification of store displays in tobac-
co-free pharmacies to place NRT in prominent posi-
tions formerly occupied by tobacco products, including 
the power wall, suggests that these stores now promote 
tobacco cessation rather than tobacco use. These displays 
communicate an abstinence message even if they do not 
result in greater onsite sales of NRT. Finally, our findings 
suggest that all pharmacies could promote pharmacist 
counselling on NRT use more effectively, increasing the 
chances that tobacco users will successfully quit.
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